×ðÁú¿­Ê±

EN
EN
  • ÓªÒµ×Éѯ

    Öйú£º

    Email: marketing@medicilon.com.cn

    ÓªÒµ×ÉѯרÏߣº400-780-8018

    £¨½öÏÞЧÀÍ×Éѯ £¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©

    ´¨É³×ܲ¿µç»°: +86 (21) 5859-1500

    ÍâÑó£º

    +1(781)535-1428(U.S.)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com

ÔÚÏßÁôÑÔ¡Á
µã»÷Çл»
News information
ÐÂÎÅ×ÊѶ

×ðÁú¿­Ê±PROTACÒ©Îï·¢Ã÷Ñо¿Æ½Ì¨

2021-04-30
|
»á¼ûÁ¿£º
¹Ø×¢×ðÁú¿­Ê±Medicilon¹«ÖںŠ£¬ÔÚÖ÷ҳ̸Ìì¿ò»Ø¸´¡°ÊµÑ鱨¸æ¡± £¬¼´¿ÉÉó²é¡°Ä³Ä¿µÄÂѰ×PROTAC-POIÌåÍâɸѡ¡±µÄÏêϸʵÑ鱨¸æ£¡

×ðÁú¿­Ê±PROTACÒ©Îï·¢Ã÷Ñо¿Æ½Ì¨

PROTACÊÖÒÕ×÷ÓûúÖÆÆæÒì

PROTACÊÖÒÕ×÷ÓûúÖÆ

  • 1.PROTAC·Ö×Óͨ¹ýÆäÒ»¶ËµÄ°ÐÂѰ×ÅäÌ壨POI Ligand£©ÌØÒìÐÔʶ±ð²¢Á¬Ïµ°ÐÂѰ× £¬Í¨¹ýÆäÁíÒ»¶ËµÄE3·ºËØÅþÁ¬Ã¸ÅäÌ壨E3 Ligase Ligand£©ÌØÒìÐÔʶ±ð²¢Á¬ÏµE3 Ligase£»

  • 2.ÐγÉP O I - P R O T A C - E 3ligaseÈýÔª¸´ºÏÌ壻

  • 3.ÔÚ´ËÈýÔª¸´ºÏÌåÖÐ £¬°ÐÂѰ×POI±»E3 ligase·ºËØ»¯ÐÞÊÎ £¬·ºËØ»¯ÐÞÊÎÁ˵ÄPOIËæºó±»ÂѰ×øÌåʶ±ð²¢½µ½â £¬ÓÉ´ËÒÖÖÆ°ÐÂѰ׵Ĺ¦Ð§

PROTACÊÖÒÕÔÚÒ©ÎïÑз¢·½ÃæµÄÓÅÊÆ
¸Ä±ä°ÐµãµÄ¡°²»¿É³ÉÒ©ÐÔ¡±£¨undruggable£©
PROTACµÄ×÷Ó÷Ö×Ó»úÖÆÊÇͨ¹ý·ºËØ-ÂѰ×øϵһÇнµ½â°ÐÂѰ× £¬²¢·Çͨ¹ý¾ºÕùÁ¬ÏµÒԹرհÐÂѰ׹¦Ð§Çø¶øÊ©Õ¹ÂѰ׹¦Ð§ÒÖÖÆ×÷Óà £¬Òò´ËPROTAC¶Ô°ÐÂѰ×ʶ±ðÁ¬ÏµÇø·×Æç¶¨·ÇµÃÊÇ»îÐÔÇø £¬½áЭÁ¦Ò²·×Æç¶¨±ØÐèÊǸßÇ׺ÍÁ¦£»ÕâʹµÃһЩȱ·¦¸ßÇ׺ÍÁ¦Ð¡·Ö×ÓÁ¬ÏµµÄ¡°²»¿É³ÉÒ©ÐÔ¡±°ÐÂѰ×Äð³É¡°¿É³ÉÒ©ÐÔ¡±;
¸ßЧÐÔ
¹Å°åС·Ö×ÓÒÖÖÆ¼Áͨ¹ý¾ºÕùÁ¬Ïµ°ÐÂѰ׻îÐÔ¹¦Ð§Óò¶øÒÖÖÆ°ÐÂѰ׹¦Ð§ £¬ËùÐèС·Ö×ÓµÄÁ¿ÍùÍù½Ï´ó£»¶øPROTACͨ¹ý·ºËØ-ÂѰ×øϵһÇнµ½â°ÐÂѰ×ÒÔɨ³ý°ÐÂѰ׹¦Ð§ £¬¹Ê¾ßÓпÉÑ­»·Ê¹ÓÃÐÔ¡¢ÓÃÁ¿µÍºÍ¸ßЧÐÔµÄÌØµã¡£
ÎÞÃâÒßÔ­ÐÔ
Ó뿹ÌåÒ©ÎïÏà±È £¬PROTAC²»»áÒý·¢¿¹Ò©¿¹Ì屬·¢¡£
×ÛÉÏ £¬PROTACÒѳÉΪҩÎïÑз¢ÁìÓòµÄÐÂÐËÀûÆ÷ £¬ÔÚº£ÄÚÍⱸÊÜ¿ÆÑе¥Î»¼°Ò©ÆóËù×·Åõ¡£
×ðÁú¿­Ê±PROTACÊÖÒÕЧÀÍÏÈÈÝ
°Ð±êÂѰ×PROTAC-POIµÄÉè¼ÆºÏ³É
×ðÁú¿­Ê±»ã×ÜÁËÄ¿½ñÊ¢ÐеÄÈÈÃÅPOIÅäÌå £¬²î±ð×éÖ¯ÀàÐ͵ÄE3ligaseÅäÌå £¬²¢ÇÒ½¨ÉèÁ˺¬Êý°ÙÖÖÅþÁ¬·Ö×ÓµÄlinker¿â¡£
±ðµÄ £¬×ðÁú¿­Ê±³ÉÊìµÄÅÌËã»ú¸¨ÖúÒ©ÎïÉè¼ÆÊÖÒÕÆ½Ì¨ £¬´ó´óÌá¸ßPROTAC-POIµÄÉè¼ÆºÏ³ÉÖÊÁ¿¡£
PROTAC-POIµÄÌåÍâɸѡ

HEK 293TÎÈתÖêϸ°û£¨POI-EGFP£©¸ßͨÁ¿É¸Ñ¡

ʹÓûùÒòÇÃÈëÊÖÒÕ¹¹½¨µÄ¡°ÄÚÔ´ÂѰ×-EGFP¡±293TÎÈתÖêϸ°û £¬¶ÔPROTAC·Ö×Ó¾ÙÐиßͨÁ¿É¸Ñ¡ £¬ÅÌËãDC50¡£

Percentage reduction in POI-EGFP fusion protein level

Percentage reduction in POI-EGFP fusion protein level

Western Blot£¨WB£©

ͨ¹ýWBʵÑé¼ì²â³õɸµ½µÄPROTAC·Ö×Ӷ԰бêÂѰ׵Ľµ½âÄÜÁ¦ £¬ÆÊÎöDC50Öµ¡£

Fig. 2 Western Blot Images showing POI degradation by PROTAC-POI

Fig. 2 Western Blot Images showing POI degradation by PROTAC-POI

ϸ°û¶¾ÐÔʵÑ飨CCK-8»òCTG·¨£©

¼ì²âÉÏÊöɸѡµ½PROTC-POI¶Ô°©Ï¸°ûÔöÖ³ÒÖÖÆÄÜÁ¦ £¬ÆÊÎöIC50Öµ¡£

»úÖÆ¼ì²â

a. ¼ì²âPROTACÊÇ·ñͨ¹ýE3 CRBN¶Ô°ÐÂѰ׾ÙÐнµ½â¡£

Fig. 2 Western Blot Images showing POI degradation by PROTAC-POI

Fig. 2 Western Blot Images showing POI degradation by PROTAC-POI

b. ÌØÒìÐÔ¼ì²â£ºÍ¨¹ýʹÓÃLC-MS/MS¾ÙÐÐÂѰ××éѧÆÊÎö £¬È·¶¨PROTAC½µ½âÂѰ׵ÄÌØÒìÐÔ£»Ê¹ÓÃKINOMEscanÆÊÎöPROTAC¶Ô¼¤Ã¸Á¬ÏµµÄÌØÒìÐÔ¡£

Proteasome system mediates PROTAC-POI-induced POI Degradation

Proteasome system mediates PROTAC-POI-induced POI Degradation

Ö×Áöϸ°ûµÄÔöÖ³ÒÖÖÆÐ§Ó¦

ʹÓÃCCK-8»òCTG·¨ £¬¼ì²âPROTAC¶ÔÖ×Áöϸ°ûµÄÔöÖ³ÒÖÖÆÐ§¹û¡£

Proliferation inhibition effects of POI in the indicated cell lines at 120 h after treatment

Proliferation inhibition effects of POI in the indicated cell lines at 120 h after treatment

PROTAC-POIµÄ¶¯ÎïÌåÄÚҩЧɸѡ

CDXСÊóÖ×ÁöÄ£×Ó

½«ÏìÓ¦°©ÖÖϸ°ûÏµÒÆÖ²µ½ÂãÊó»òNSGСÊóÌåÄÚ £¬½¨ÉèÆ¤ÏÂÁö»òԭλÁöÄ£×Ó £¬Í¨¹ý¿Ú·þ¡¢¹àθ»ò¾²Âö¸øÒ© £¬¼ì²âÌåÍâɸµ½µÄPROTAC-POI¶ÔÊóÌåÄÚÖ×ÁöÉú³¤µÄÒÖÖÆÐ§¹û¡£

CDXСÊóÖ×ÁöÄ£×Ó

PDXСÊóÖ×ÁöÄ£×Ó

½«Ö×Áö×éÖ¯ÒÔ×éÖ¯¿éµÄÐÎÊ½ÒÆÖ²µ½NSGСÊóÌåÄÚ £¬ÕâЩÖ×Áö×éÖ¯ÔÚNSGСÊóÌåÄÚ¼á³ÖÁËԭʼÖ×ÁöµÄÉúÎïÑ§ÌØÕ÷ £¬ÓëÁÙ´²ÌØÕ÷ÏàËÆ¶È¸ü¸ß¡£Ê¹ÓÃPDXСÊóÄ£×Ó¼ì²âPROTAC-POI¶ÔÌåÄÚÖ×ÁöÉú³¤µÄÒÖÖÆÐ§¹û¡£

PDXСÊóÖ×ÁöÄ£×Ó

PK/PDÑо¿¡¢Ò©Ñ§ÆÊÎö¡¢Ò©Îï´úл¶¯Á¦Ñ§Ñо¿ºÍÇå¾²ÐÔÆÀ¼Û
¶Ô¶¯ÎïÌåÄÚҩЧ¼ì²âɸѡ»ñµÃµÄÀíÏëµÄPROTAC-POI¾ÙÐÐPK/PDÑо¿¡¢Ò©Ñ§ÆÊÎö¡¢Ò©Îï´úл¶¯Á¦Ñ§Ñо¿ºÍÇå¾²ÐÔÆÀ¼Û £¬²¢»ã×ÜʵÑéЧ¹ûºÍÖÊÁϾÙÐÐINDÉ걨 £¬ÒÔÖúÁ¦¿Í»§¼ÓËÙPROTAC-POIÒ©ÎïµÄÑз¢Àú³Ì¡£
ɨÃèÏ·½¶þάÂë £¬¹Ø×¢×ðÁú¿­Ê±Medicilon¹«ÖںŠ£¬ÔÚÖ÷ҳ̸Ìì¿ò»Ø¸´¡°ÊµÑ鱨¸æ¡± £¬¼´¿ÉÉó²é¡°Ä³Ä¿µÄÂѰ×PROTAC-POIÌåÍâɸѡ¡±µÄÏêϸʵÑ鱨¸æ£¡

×ðÁú¿­Ê±Medicilon¹«ÖÚºÅ


ÁªÏµ×ðÁú¿­Ê±
Email: marketing@medicilon.com.cn
µç»°: +86 (21) 5859-1500£¨×Ü»ú£©

Ïà¹ØÐÂÎÅ
¡Á
ËÑË÷ÑéÖ¤
µã»÷Çл»
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿